Last reviewed · How we verify

NCT05121922

Sense of Coherence and Empowerment at Patients With MUPS

Status unknown NA Last updated 9 November 2022
What this trial tests

NA trial testing Metacognitive Therapy in Medically Unexplained Symptoms in 30 participants. Status unknown.

Timeline
15 August 2021
Primary endpoint
30 June 2023
30 June 2025

Quick facts

Lead sponsorUniversity of Oslo
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment30
Start date15 August 2021
Primary completion30 June 2023
Estimated completion30 June 2025
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

University of Oslo

Who can join

18 and older, any sex, with Medically Unexplained Symptoms or Sense of Coherence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study on Metacognitive therapy in general practice in Norway. The intervention is a small pilot study to examine whether Metacognitive therapy is feasible in an ordinary general practice. Will the physicians be capable to learn and provide the therapy method for their patients with MUPS and is is possible to implement this in an ordinary general practice routine? Both physicians and their patients will be asked to respond to a questionnaire on perceived utility of the treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metacognitive Therapy

Trials testing the same drug.

Other recruiting trials for Medically Unexplained Symptoms

Currently open trials in the same condition.

Other University of Oslo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05121922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing